Search
Mink Therapeutics Inc
INKTAdd to Watchlist
12.350USD
0.0000.00%
Close 09-23 16:00（ET）
61.50MMarket Cap
LossP/E TTM
Mink Therapeutics Inc (INKT) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts giving stock ratings to Mink Therapeutics Inc in the past month.
Buy
0 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
39.000USD+222.05%
INKT Analyst Recommendation Trends
In the current month, INKT has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. INKT average Analyst price target in the last month is 39.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
Financial Forecasting
Based on analysts' estimates, INKT EPS is projected to reach -0.350 in FY2026Q3, following reported EPS of -0.623 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.82
-0.77
-0.60
-0.35
-0.39
Actual
-0.56
-0.57
-0.62
--
--
Surprise
+32.29%
+25.77%
-3.79%
--
--
FAQs
What is Mink Therapeutics Inc's price target?
Analysts forecast that Mink Therapeutics Inc's price target is USD 39.00, with the highest forecast at USD 43.00 and the lowest forecast at USD 35.00.
How have Mink Therapeutics IncINKT's recent earnings per share performed?
The market expectation was USD -0.62, while Mink Therapeutics IncINKT's earnings per share (EPS) for the previous quarter was USD -0.57. EPS for the next quarter is expected at USD -0.35.
What is the analyst rating for Mink Therapeutics Inc?
Based on the ratings of Mink Therapeutics Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.